LGALS3 and metabolic dysfunction-associated steatohepatitis: The pharmacological inhibitors of Galectin-3 have demonstrated efficacy in treating various diseases, including nonalcoholic steatohepatitis and pulmonary fibrosis in animal models, and even in humans (20, 33–35).